Breast Cancer Research and Treatment

, Volume 74, Issue 1, pp 25–31

C-myc oncogene amplification in ductal carcinoma in situ of the breast

Authors

  • Sebastian Aulmann
    • Department of PathologyUniversity of Heidelberg
  • Martin Bentz
    • Department of Internal Medicine IIIUniversity of Ulm
  • Hans Peter Sinn
    • Department of PathologyUniversity of Heidelberg
Article

DOI: 10.1023/A:1016061327812

Cite this article as:
Aulmann, S., Bentz, M. & Sinn, H.P. Breast Cancer Res Treat (2002) 74: 25. doi:10.1023/A:1016061327812

Abstract

The c-myc oncogene is frequently activated in invasive breast cancer and has been associated with high nuclear grade, lymph node metastasis and poorer disease outcome. We have examined c-myc oncogene amplification using fluorescence in situ hybridization in a series of 96 pure DCIS. Additionally we assessed amplification and expression of the Her2 and bcl-2 oncogenes. The findings were compared with clinicopathological data, Ki-67 proliferative index and hormone receptor status. We observed c-myc oncogene amplification in 19 tumours (20%). These cases were significantly associated with an average of 38% higher proliferative activity (p = 0.045), a 43% larger tumour size (p = 0.029) and the otherwise rare micropapillary subtype (p = 0.0005). Concluding the c-myc oncogene appears to be involved in the development of a more aggressive phenotype of DCIS.

bcl-2c-mycDCISFISHHer2
Download to read the full article text

Copyright information

© Kluwer Academic Publishers 2002